Search

Whither pertussis?

This article discusses the rising prevalence of pertussis disease in countries which have switched to acellular vaccines.

Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy

We therefore speculate that removal of wP from the vaccine schedule contributed to the observed rise in IgE-mediated food allergy among Australian infants

Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial

The monovalent acellular pertussis vaccine is immunogenic and safe in neonates

Inequity of antenatal influenza and pertussis vaccine coverage in Australia: the Links2HealthierBubs record linkage cohort study, 2012–2017

Pregnancy and early infancy are increased risk periods for severe adverse effects of respiratory infections. Aboriginal and/or Torres Strait Islander (respectfully referred to as First Nations) women and children in Australia bear a disproportionately higher burden of respiratory diseases compared to non-Indigenous women and infants. Influenza vaccines and whooping cough (pertussis) vaccines are recommended and free in every Australian pregnancy to combat these infections.

Immune impacts of infant whole-cell and acellular pertussis vaccination on co-administered vaccines

We compared the effect of a heterologous wP/aP/aP primary series (hereafter mixed wP/aP) versus a homologous aP/aP/aP primary schedule (hereafter aP-only) on antibody responses to co-administered vaccine antigens in infants and toddlers.

Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule

The purpose of this double-blind, randomised, controlled trial is to compare allergic outcomes in children following vaccination with acellular pertussis (aP) antigen (standard of care in Australia) given at 2 months of age versus whole cell pertussis (wP) in the infant vaccine schedule.

The Kids Research Institute Australia research ensures kids are protected against whooping cough

Research by The Kids Research Institute Australia will soon ensure young children are better protected against whooping cough.

Unlocking the immunology of whooping cough vaccines to guide the development of improved vaccines and schedules in Australia

Ruth Peter Thornton Richmond PhD MBBS MRCP(UK) FRACP Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG) Head, Vaccine Trials Group

World-first nasal spray whooping cough vaccine aims to protect young bubs

Tiny babies could soon have much-needed protection from community transmission of potentially deadly whooping cough thanks to a world-first nasal spray vaccine being trialed at The Kids Research Institute Australia.

Deborah Lehmann Research Award Opportunity

The Deborah Lehmann Research Award in Paediatric Infectious Disease Research is a funding mechanism to support the training and development of early- to mid-career researchers (EMCR) or Higher Degree by Research (HDR) students who are nationals from the Pacific Region working in or outside their hom